M. Homerin

Centre Hospitalier René-Dubos — France

Biochemistry, Genetics and Molecular Biology · Life Sciences

11h-index4.5kcitations23works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Virus-based gene therapy research(11), CAR-T cell therapy research(7), Cancer Research and Treatments(7), Helicobacter pylori-related gastroenterology studies(5), Gastroesophageal reflux and treatments(5)

Publications23 total

Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
Journal of Clinical Oncology·2023· 32 cited
Vaccinia-based oncolytic immunotherapy Pexastimogene Devacirepvec in patients with advanced hepatocellular carcinoma after sorafenib failure: a randomized multicenter Phase IIb trial (TRAVERSE)
OncoImmunology·2019· 126 citedOpen Access
A phase I dose escalation trial evaluating the impact of an in situ immunization strategy with intra-tumoral injections of Pexa-Vec in combination with ipilimumab in advanced solid tumors with injectable lesions
Annals of Oncology·2018Open Access
Single intravenous preoperative administration of the oncolytic virus Pexa-Vec to prime anti-tumor immunity.
Journal of Clinical Oncology·2018· 8 cited
A phase Ib trial of JX-594 (Pexa-Vec), a targeted multimechanistic oncolytic vaccinia virus, in combination with low-dose cyclophosphamide in patients with advanced solid tumors
Annals of Oncology·2017· 3 cited
TG6002: A novel oncolytic and vectorized gene pro-drug therapy approach to treat glioblastoma.
Journal of Clinical Oncology·2017· 11 cited
Vectorized gene therapy of liver tumors: proof-of-concept of TG4023 (MVA-FCU1) in combination with flucytosine
Annals of Oncology·2016· 30 citedOpen Access
2219 Intratumoral injection of the oncolytic immunotherapeutic Pexa-Vec (JX-594) in liver tumors and hepatocellular carcinoma: Recommendations for clinical practice
European Journal of Cancer·2015· 1 cited
Randomisierte Phase-IIb-Studie mit Pexa-Vec (pexastimogene devacirepvec; JX-594), eine onkolytische Immuntherapie mit Best Supportive Care (BSC) gegen BSC allein bei Patienten mit Leberzellkarzinom (HCC) und fehlgeschlagener Sorafenib-Behandlung (TRAVERSE)
Zeitschrift für Gastroenterologie·2015· 1 cited
Phase IIb randomized trial of Pexa-Vec (pexastimogene devacirepvec; JX-594), a targeted oncolytic vaccinia virus, plus best supportive care (BSC) versus BSC alone in patients with advanced hepatocellular carcinoma who have failed sorafenib treatment (TRAVERSE).
Journal of Clinical Oncology·2013· 9 cited
Vectorized gene therapy of liver tumors: Safety and proof of concept of TG4023 (MVA-FCU1)/5-FC combination.
Journal of Clinical Oncology·2012· 1 cited
Phase IIb randomized trial of JX-594, a targeted multimechanistic oncolytic vaccinia virus, plus best supportive care (BSC) versus BSC alone in patients with advanced hepatocellular carcinoma who have failed sorafenib treatment (TRAVERSE).
Journal of Clinical Oncology·2012· 4 cited
Comparison of the effects of fasting morning, fasting evening and fed bedtime administration of tenatoprazole on intragastric pH in healthy volunteers: a randomized three‐way crossover study
Alimentary Pharmacology & Therapeutics·2006· 24 citedOpen Access
Characterization of the inhibitory activity of tenatoprazole on the gastric H+,K+-ATPase in vitro and in vivo
Biochemical Pharmacology·2006· 60 cited
A comparative study of the early effects of tenatoprazole 40 mg and esomeprazole 40 mg on intragastric pH in healthy volunteers
Alimentary Pharmacology & Therapeutics·2005· 39 citedOpen Access
Tenatoprazole, a novel proton pump inhibitor with a prolonged plasma half‐life: effects on intragastric pH and comparison with esomeprazole in healthy volunteers
Alimentary Pharmacology & Therapeutics·2004· 90 citedOpen Access
Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
Journal of Clinical Oncology·2000· 3.8k cited
Leucovorin a nd F luorouracil W ith o r W ithout O xaliplatin as F irst-Line T reatment i n A dvanced C olorectal C ancer
2000
L'oxaliplatine améliore le traitement de première ligne des cancers colorectaux métastatiques
La Revue de Médecine Interne·1998
Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: A phase II multicentric study
Annals of Oncology·1998· 227 citedOpen Access
page 1 of 2Next →

Frequent Co-authors

Nicolas Stojkowitz(6), Monika Lusky(6), Jean‐Marc Limacher(5), David H. Kirn(5), Caroline J. Breitbach(5), Arié Figer(4), Michel Seymour(4), C. Boni(4), H. Cortés-Funes(4), Christophe Louvet(4), Daniel Hendler(4), Filippo de Braud(4), Riccardo Lencioni(4), Aimery de Gramont(3), Abdel Hmissi(3), Jim Cassidy(3), Andrés Cervantes(3), Gilles Freyer(3), D. Papamichael(3), N Le Bail(3)